-
China-Led International Real-World Study: TACE Plus Immunotherapy Boosts Survival Beyond 26 Months in Unresectable HCC
The study not only fills a gap in international guidelines regarding treatment strategies for advanced HCC, but also injects fresh insight into global HCC management through a “China‑led approach,”marking China’s…
-
ILCA Roundtable | MDT: Optimizing HCC Treatment Strategies – Insights from the TALENT Series Studies
In recent years, advances in systemic therapy have offered hope for advanced liver cancer patients, but traditional single treatments remain limited, highlighting the need for new approaches. Combining systemic therapy with local treatments has become a key trend, with multidisciplinary team (MDT) collaboration now a global standard. Experts from surgery, interventional radiology, oncology, and more…
-
Prof. Qiang Wei: Gathering Global Expertise to Shape a New Landscape in Uro-Oncology at the West China Tianfu Academic Conference
Editor’s Note: The 9th West China Uro-Oncology Tianfu Academic Conference and the 11th Annual Meeting of the Sichuan Anti-Cancer Association Genitourinary Tumor Committee was successfully held in Chengdu from November…
-
Prof. Hao Zeng: Key Takeaways from the West China Uro-Oncology Tianfu Conference and Advances in Precision Prostate Cancer Management
Editor’s Note: From November 10–16, 2025, the 9th West China Uro-Oncology Tianfu Academic Conference and the 11th Annual Meeting of the Genitourinary Tumor Committee of the Sichuan Anti-Cancer Association were…
-
Prof. Pei Dong: From “Effective” to “Precise” — Current Status and Future Directions of Immunotherapy in Renal Cell Carcinoma
With the rapid progress of clinical research, immunotherapy has demonstrated substantial value across multiple treatment settings in renal cell carcinoma (RCC). In particular, immune-based combination regimens have reshaped the treatment landscape of advanced RCC. At the 9th West China Uro-Oncology Tianfu Academic Conference & the 11th Annual Meeting of the Sichuan Anti-Cancer Association Genitourinary Tumor Committee, Professor Pei Dong from Sun Yat-sen University…
-
West China UroOncology Tianfu Conference丨Professor Wei Xue Shares the Renji Experience in Comprehensive Prostate Cancer Management
01 Oncology Frontier – Urology Frontier: Your team was the first internationally to propose Raman spectroscopy–based noninvasive diagnosis using prostatic fluid. How do these innovations reshape the traditional diagnostic pathway…
-
Prof. Raynier Devillier: Three Key Focuses in HSCT for the Elderly—Disease Status, Conditioning Intensity, and Donor Selection
With the aging population, the demand for hematopoietic stem cell transplantation (HSCT) among elderly patients with hematologic malignancies is growing, yet clinical decision-making faces increasingly complex challenges. In the process…
-
Professor Alejandro Madrigal: The Path to Breakthrough for the Localization of CAR-T Cell Therapy in Latin America
In the global wave of medical innovation, emerging therapies such as CAR-T cell therapy have brought revolutionary hope for major diseases, including malignancies. However, their widespread adoption and application face significant regional imbalances, with low- and middle-income countries encountering numerous structural barriers in accessing these frontier technologies. From November 13 to 16, 2025, the 2025 International Conference on Cell and Immunotherapy (CTI 2025) was held in Hangzhou, Zhejiang. During the conference, Oncology Frontier – Hematology specially invited Professor Alejandro Madrigal from University College London (UCL) to discuss, from an international perspective and using Mexico as a case study, the core challenges Latin America faces in promoting equitable access to medical resources and introducing cutting-edge therapies.
Connecting Medical Expertise through Media